Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5347350 | 0.98 | TAAR1 (0.53) | TAAR1CAPN1GRM2GRM3SLC1A3 | |
| SCHEMBL934548 | 0.90 | TAAR1 (0.53) | TAAR1CAPN1GRM2GRM3SLC1A3 | |
| SCHEMBL28304375 | 0.89 | NAAA (0.52) | TAAR1CAPN1GRM2GRM3SLC1A3 | |
| SCHEMBL934620 | 0.87 | NAAA (0.55) | TAAR1GRM2GRM3SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL27525503 | 0.87 | NAAA (0.51) | TAAR1CAPN1GRM2GRM3SLC1A3 | |
| Hydrochloric Acid SCHEMBL27560544 | 0.85 | NAAA (0.50) | TAAR1CAPN1GRM2GRM3SLC1A3 | |
| SCHEMBL7331954 | 0.83 | TAAR1 (0.54) | TAAR1GRM2GRM3SLC1A3SLC1A2 | |
| SCHEMBL599876 | 0.82 | KEAP1 (0.54) | TAAR1GRM2GRM3SLC1A3SLC1A2 | |
| SCHEMBL28295940 | 0.80 | CHEK2 (0.47) | CAPN1ALDH1A1HDAC8HDAC6LMNA | |
| SCHEMBL3353073 | 0.80 | ALDH1A1 (0.53) | TAAR1GRM2GRM3SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | claimed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | claimed |
| US-20240101538-A1 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2024-03-28 | — | — | US | disclosed |
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2091947-A2 | GLUCOKINASE ACTIVATORS | Takeda San Diego, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008079787-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-7358276-B2 | for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent | UCB, S.A. (BE) | 2008-04-15 | — | — | US | disclosed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | disclosed |
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101538-A1 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | AURKC, AURKA, AURKB | TAAR1 4655/4885CAPN1 3230/4885GRM2 4630/4885 |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | TAAR1 1231/4885CAPN1 4358/4885GRM2 2296/4885 |
| US-20050171188-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | TAAR1 3093/4885CAPN1 854/4885GRM2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.